Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pranoprofen→

Pranoprofen Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
52549-17-4
Molecular formula
C15H13NO3
Molecular weight
255.27 g/mol
Drug class
Propionic-acid non-steroidal anti-inflammatory drug (NSAID)ophthalmic cyclooxygenase inhibitor
Mechanism of action
Inhibits cyclooxygenase-mediated prostaglandin synthesis, reducing ocular inflammation, pain and inflammatory miosis. Topical ophthalmic administration produces local anti-inflammatory effects.
Indications / reported uses
  • Treatment of postoperative ocular inflammation and pain, and selected inflammatory eye conditions such as conjunctivitis or blepharitis, according to local product authorisation.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=pranoprofen · https://www.ncbi.nlm.nih.gov/mesh/?term=pranoprofen · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pranoprofen Environmental Risk Assessment (ERA) (the Pranoprofen ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.